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T he rapid technological development of computed tomography coronary angiography (CTCA) over the past decade has signifi-cantly increased our ability to image the heart and coronary arter-
ies noninvasively. Essential to performing a successful CTCA examina-
tion is obtaining adequate image quality, which depends on a low and 
stable heart rate and motion-free heart. Despite significant technical ad-
vances, such as using 64-row and 320-row CTCA, heart rate control re-
mains an important factor in optimizing the image quality of CTCA (1). 
Thus, to achieve heart rate reduction, beta-blocking medication or calci-
um antagonists are routinely administered prior to CTCA examinations. 
The use of beta-blockers is limited, however, due to contraindications; 
in recent studies, a substantial portion of patients requiring heart rate 
reduction have contraindications to beta-blockers (1, 2). Thus, there ex-
ists a need for alternative heart-rate-lowering premedication. Ivabradine 
is a promising heart-rate-lowering agent that reduces the heart’s natural 
pacemaker activity by inhibiting the funny ion (Iƒ) channel (3). In a 
recent study, Pichler et al. (4) has compared ivabradine and metoprolol 
and found that heart rate reduction was significantly more in patients 
treated with ivabradine than patients receiving long-term beta-blocker 
therapy.
The aim of the present study was to assess the effectiveness of ivabra-
dine on heart rate reduction and improving image quality of ECG-gated 
multidetector computed tomography (MDCT) coronary angiography.
Materials and methods
The study group included 110 consecutive patients (25 females, 85 
males; mean age, 59±13.8 years; age range, 33–78 years) with suspected 
coronary artery disease. The study was approved by the institutional eth-
ics committee, and written informed consent was obtained from all sub-
jects prior to the study. Patient characteristics are summarized in Table 
1. The patients were all in sinus rhythm. Patients with atrial fibrillation, 
II or III degree atrio-ventricular-block, impaired renal function (creati-
nine >1.5 mg/dL), known allergy to iodinated contrast media, thyroid 
disease, known arrhythmias, or left ventricular ejection fraction <30% 
were excluded from the study. Patients who had coronary stents or had 
previously undergone bypass surgery were also excluded. In addition, 
cases with premature beats, severe respiratory artifacts or severe calcifica-
tions that could hamper image quality were excluded.
A total of 146 patients were referred for CTCA over a period of three 
months. Twenty-two (15%) were excluded due to the exclusion crite-
ria described above. Fourteen patients had a heart rate below 60 beats 
per minute (bpm), thus premedication was not required. Eleven of the 
remaining patients (10%) had contraindications to beta-blockers, such 
as asthma and severe chronic obstructive pulmonary disease, and these 
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PURPOSE
The objective of our study was to assess the effect of ivabra-
dine on image quality of ECG-gated multidetector computed 
tomography (MDCT) coronary angiography.
MATERIALS AND METHODS
Computed tomography coronary angiography (CTCA) was 
performed on two groups. In Group 1 (n=54), an intravenous 
beta-blocker was administered to patients with a heart rate 
>70 beats per minute (bpm) just before CTCA. In Group 2 
(n=56), oral ivabradine 5 mg was administered twice a day 
for three days prior to CTCA examination to patients with a 
heart rate >70 bpm and contraindication to beta-blockers. Im-
ages acquired on two different MDCT scanners were scored 
in terms of image quality of the coronary artery segments us-
ing a 5-point grading scale (Grade 1, unreadable; Grade 5, 
excellent).
RESULTS
The mean heart rates during CTCA were 64±6.7 bpm for 
Group 1 and 59±4.1 bpm for Group 2 (P < 0.05). Mean heart 
rate reduction was 9±5% and 14±8% for Groups 1 and 2, 
respectively (P < 0.001). A total of 880 segments were evalu-
ated in 110 patients. When the best reconstruction interval 
was used, 89.8% and 95.5% of all the coronary segments 
showed acceptable image quality in Groups 1 and 2, respec-
tively. Acceptable image quality of the middle right coronary 
artery was obtained in 78.3% of Group 1 and 92.4% of Group 
2. These ratios for the other segments were 88.4% for Group 
1 and 95.2% for Group 2.
CONCLUSION
Reduction of heart rates with ivabradine premedication im-
proves the image quality of CTCA. It should be considered as 
an alternative drug, particularly in patients with contraindica-
tions to beta-blockers.
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intravenously at 5 mL/s, followed by 
40 mL saline at 2.5 mL/s. 
Retrospective ECG-gated reconstruc-
tions were performed between the lev-
els containing the first several centim-
eters of the left and right coronary ar-
teries. The best reconstruction window 
was then selected, and ECG-gated re-
construction was performed for whole 
axial resource images. The reconstruct-
ed images were then transferred to a 
post-processing workstation (Vitrea 2, 
Vital Images, Minnetonka, Minnesota, 
USA; Hewlett-Packard xw8200 worksta-
tion with dual Xeon processors and 4 
GB of RAM, GE Healthcare, Waukesha, 
Wisconsin, USA) for further analysis 
with specialized software. Axial source, 
multiplanar reconstruction, maximum 
intensity projection, and volume-ren-
dered images were used for assessment 
of the coronary arteries. Image qual-
ity was assessed by two radiologists 
who independently reviewed the im-
ages without knowledge of the other’s 
interpretations.
The two radiologists independently 
assessed eight of 15 coronary seg-
ments differentiated according to the 
American Heart Association classifi-
cation: the left main coronary artery 
(LMCA); the proximal and middle seg-
ments of the left anterior descending 
(LAD) and left circumflex (LCX) coro-
nary arteries; and the proximal, mid-
dle, and distal segments of the right 
coronary artery (RCA). A 5-point scale 
was used to assess the image quality 
of each coronary segment: 5, no mo-
tion artifacts; 4, minor artifacts (mild 
blurring); 3, moderate artifacts (mod-
erate blurring without discontinuity); 
2, severe artifacts (doubling or discon-
tinuity in the course of the coronary 
segments); and 1, unreadable (vessel 
structures not differentiable) (Fig.). A 
score of 4 or higher was considered ac-
ceptable image quality. The number of 
patients with acceptable image quality 
in each coronary segment was calcu-
lated, and the results were compared 
between the two groups.
Statistical analysis
Statistical analysis was performed us-
ing a commercially available software 
(Statistical Package for Social Sciences, 
version 16, SPSS Inc., Chicago, Illinois, 
USA). Continuous variables are present-
ed as the mean value±standard devia-
tion. Categorical variables are present-
ed as absolute number (percentage). 
Inter-observer agreement for image 
quality and best reconstruction interval 
readout were calculated with Cohen’s  
statistics. Pearson’s correlation analysis 
was performed to compare the image 
quality scores of all segments togeth-
er and the scores for separate arteries 
(RCA, LMCA, LAD, and LCX) with the 
average heart rate and its standard de-
viation during CT scanning. A P value 
of less than 0.05 indicated a statistically 
significant difference.
Results
All subjects had a sinus rhythm on 
ECG during CT. The mean heart rate 
prior to CTCA was 71±9.8 bpm for 
Group 1 and 65±7.8 bpm for Group 2. 
The mean heart rate during CTCA was 
64±6.7 bpm for Group 1 and 59±4.1 
bpm for Group 2 (P < 0.05). Mean heart 
rate reduction was 9±5% and 14±8% 
for Groups 1 and 2, respectively (P < 
0.001) (Table 2). Coronary artery ste-
nosis was detected in two patients in 
Group 1 and four patients in Group 2 
on CTCA. A total of 880 segments were 
evaluated in 110 patients. When the 
best reconstruction interval was used, 
89.8% and 95.5% of all the coronary 
segments showed acceptable image 
quality in Groups 1 and 2, respectively. 
Acceptable image quality of the middle 
RCA was obtained in 78.3% of Group 
1 and 92.4% of Group 2. These ratios 
for the other segments were 88.4% and 
95.2% for Groups 1 and 2, respectively. 
Table 3 shows the percentage of pa-
tients with images of acceptable qual-
ity (score 4 or more) of each coronary 
segment. Table 4 shows the distribu-
tion of image quality scores of the 880 
segments for both reviewers.
The 60%–70% reconstruction inter-
val in the cardiac cycle was judged by 
both reviewers to provide the best im-
age quality for assessing the coronary 
arteries in both groups. Inter-observer 
patients were treated with ivabradine 
premedication. Intravenous beta-
blocker premedication was adminis-
tered to 10 (10%) of the remaining 
patients who had chronic beta-blocker 
treatment. The remaining 89 patients 
were randomized to two groups: in 
Group 1 (n=54), an intravenous beta-
blocker (metoprolol, 5 mg/mL bolus) 
was administered to patients with a 
heart rate >70 bpm; in Group 2 (n=56), 
oral ivabradine 5 mg was administered 
twice a day for three days prior to the 
CTCA examination to patients with 
a heart rate >70 bpm. Coronary angi-
ograms were obtained in 25 (Group 1) 
and 27 patients (Group 2) using the 
Aquilion 64-MDCT scanner (Toshiba 
Medical Systems, Tokyo, Japan). 
Imaging for the remaining patients was 
acquired using the LightSpeed VCT 
64-MDCT scanner (GE Healthcare, 
Milwaukee, Wisconsin, USA).
CTCA was performed using either 
scanner with patients in the supine po-
sition. An anteroposterior scout image 
(120 kV, 50 mAs) was first performed to 
determine the boundaries of the heart. 
Computed tomography (CT) scans 
were obtained from 1 cm below the ca-
rina to the diaphragmatic face of the 
heart during a single breath-holding 
period (6–9 s). The following parame-
ters were used for both scanners: retro-
spective ECG gating; 912-channel de-
tectors along the gantry and 64-chan-
nel detectors along the z-axis; tube 
voltage 120 kV; tube current 550–750 
mA (depending on patient size); and 
scan field of view (SFOV) 50 cm. Gantry 
rotation, slice width, and helical pitch 
parameters were as follows: 0.40 s/rota-
tion (for two scanners); 0.625 mm and 
0.5 mm; and 0.18–0.24 and 0.2; for the 
first and second scanners, respectively. 
Ninety milliliters of iodinated contrast 
medium (Omnipaque 350, Amersham 
Health, Cork, Ireland) were injected 
Table 1. Patient characteristics by premedication groups
Total Beta-blocker Ivabradine  
Patients, n 110 54 56
Age (years), mean±SD 59±13 63±11 61±8   
Male gender, n (%) 87 (78) 43 (80) 44 (79)   
BMI (kg/m2), mean±SD 28±5 29±6 28±4
BMI, body mass index; SD, standard deviation.
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Figure. a–e. CT coronary angiograms show middle segment of right 
coronary artery. The vessel structure is not visible (Grade 1) (a). The 
doubling and discontinuity in the course of coronary segments are 
seen (Grade 2) (b). Moderate blurring of vascular margin is marked 
(Grade 3) (c). Mild blurring of vascular margin (Grade 4) (d) and little 
motion artifact (Grade 5) (e) are seen.
agreement for image quality rating was 
good (=0.70).
Postural hypotension occurred in one 
patient in Group 1 and two patients 
in Group 2. Local or minor systemic 
allergic reactions to contrast material, 
such as skin rashes, developed in two 
patients in Group 1 and three patients 
in Group 2. One patient had transient 
blurred vision before CTCA.
Discussion
The rapid improvement of MDCT 
technology has provided higher qual-
ity imaging and greater diagnostic ac-
curacy for the evaluation of coronary 
artery disease. Despite significant tech-
nical advances, however, heart rate 
control remains an important issue in 
optimizing image quality, even with 
64-row and 320-row CTCA. A target 
heart rate of 60 bpm or lower provides 
optimum image quality, with a heart 
rate of 65 bpm or lower providing good 
image quality in most cases (5, 6). 
A lower heart rate reduces coronary 
artery movement artifacts by increas-
ing the length of the diastolic phase 
and effectively increasing the time 
that the coronary arteries are motion-
free. In particular, the RCA and the 
LCX artery are more prone to mo-
tion artifacts, due to close proximity 
to the right and left atria, respectively 
(7–10). Graaf et al. (1) and Shapiro et 
al. (2) found that approximately half 






Table 2. Mean heart rates by premedication groups
Total Beta-blocker Ivabradine
Admission heart rate 73±7.2 75±4.8 73±5.8
Heart rate prior to CTCA (bpm) 68±8.1 71±9.8 65±7.8
Heart rate during CTCA (bpm) 62±8.5 64±6.7 59±4.1
Heart rate reduction rate (%) 11±7% 9±5% 14±8% 
bpm, beats per minute; CTCA, computed tomography coronary angiography.
Data are presented as mean±SD.
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heart rate reduction before CTCA. 
Although improved temporal resolu-
tion, with a decrease in total scanning 
time, and improved longitudinal reso-
lution have enabled image quality to 
become less dependent on heart rate, 
a clear relation between image qual-
ity and increased heart rate has been 
demonstrated, using 64-row and 320-
row CTCA (1). In addition, Rybicki et 
al. (11) found that the most common 
cause of image degradation was cardiac 
motion when using 320-row CTCA. 
Beta-blockers are generally used to 
achieve short-term heart rate reduction 
for CTCA. In the study by Graaf et al., 
(1) the target heart rate for CTCA was 
achieved with beta blockade in 73% of 
patients. Maffei et al. (12) concluded 
that heart rate control might be most 
adequately provided by intravenous 
beta-blockers without nitrates, with 
a mean heart rate reduction of 16±8 
bpm. In contrast, Shapiro et al. (2) re-
ported that the target heart rate was 
reached in only 35% of the patients 
receiving beta-blocker before CTCA. 
The use of beta-blockers is also lim-
ited due to contraindications, such as 
severe aortic stenosis, asthma, severe 
chronic obstructive pulmonary disease 
with significant bronchospasm, se-
vere peripheral vascular disease (with 
claudication), overt heart failure, sick 
sinus syndrome, second/third-degree 
heart block, and treatment with vera-
pamil. In recent studies, contraindica-
tions to beta-blockers were present in a 
substantial portion of patients requir-
ing heart rate reduction (1, 2). In the 
present study, 11 patients (10%) had 
contraindications to beta-blockers. 
These observations have prompted 
physicians to search for alternative 
heart rate-lowering premedication. 
Calcium channel blockers (diltiazem 
and verapamil) can be used to slow 
the heart rate for cardiac imaging, par-
ticularly when beta-blockers are con-
traindicated (13). In practice, however, 
the reduction rate efficiency of these 
drugs has been disappointing (14). 
Furthermore, they are contraindicated 
in patients with a history of heart fail-
ure or significantly impaired left ven-
tricle function.
Ivabradine is a selective inhibitor of 
the Iƒ channel that reduces heart rate 
in the sinus node. Therefore, it is use-
ful in patients in sinus rhythm (3). 
Ivabradine, classified as a cardiotonic 
agent, is indicated for the symptomatic 
treatment of chronic stable angina 
pectoris in patients with normal si-
nus rhythm who have a contraindica-
tion to or intolerance to beta-blockers. 
Coronary blood flow velocity increases 
after ivabradine treatment, because 
the diastolic period is prolonged (per 
cardiac beat and per minute), as ex-
pected. In addition, enhanced diastolic 
relaxation may possibly increase early 
diastolic coronary blood flow by a 
“suction effect” (15). Ivabradine is gen-
erally well tolerated, but patients may 
complain of some side effects, such 
as visual symptoms and bradycardia. 
Ivabradine is contraindicated in severe 
bradycardia, II or III degree atrio-ven-
tricular block, ejection fraction <35%, 
and severe hypotension (16). In addi-
tion, it should not be used in patients 
who are already taking CYP 3A4 inhib-
itors, such as ketoconazole, macrolides 
(such as erythromycin), and nefazo-
done (used in the treatment of human 
immunodeficiency virus) (3).
In the study by Pichler et al. (4) com-
paring two groups of oral premedica-
tion with ivabradine 15 mg or meto-
prolol 50 mg, no significant differences 
were found in the reduction of heart 
rate, but in subgroups receiving long-
term beta-blocker therapy, significant-
ly stronger heart rate reduction was 
achieved with ivabradine (4). In the 
study by Guaricci et al., (16) the com-
bination of both ivabradine and beta-
blocker yielded the best results in terms 
of heart rate reduction and rate of pa-
tients achieving the target heart rate 
compared to control, beta-blocker, and 
ivabradine groups. The mean relative 
heart rate reduction between admis-
sion and CTCA was 14.7±7.1% for con-
trols, 12.0±10.2% for the chronic beta-
blocker treatment group, 18.6±9.6% for 
the ivabradine group, and 24.0±10.4% 
for the chronic beta-blocker treatment 
and ivabradine group (for trend P < 
0.001). In their study, ivabradine pre-
medication significantly reduced heart 
rate prior to CTCA, and administra-
tion of ivabradine improved the rate 
of patients achieving the target heart 
rate of <65 bpm during CTCA com-
pared to chronic beta-blocker therapy. 
Similarly, in the present study, com-
pared to the beta-blocker group, heart 
rate control was more adequately pro-
vided in the ivabradine group, with a 
mean heart rate of 59±4.1 bpm. In ad-
dition, CTCA image quality improved 
in the group treated with ivabradine 




Proximal Middle Proximal Middle Proximal Middle Distal
Beta-blocker (n=54) 95% 96% 92% 90% 89% 88% 78% 91%
Ivabradine (n=56) 100% 100% 100% 100% 92% 94% 92% 93%
LAD, left anterior descending artery; LCX, left circumflex coronary artery; LMCA, left main coronary 
artery; RCA, right coronary artery.
Table 4. Distribution of image quality scores of 880 segments for both reviewers
Score
Number (%) of segments
Beta-blocker Ivabradine
Reviewer 1 Reviewer 2 Reviewer 1 Reviewer 2
1 7 (2.4) 9 (3.1) 2 (0.6) 4 (1.2)
2 3 (1.0) 5 (1.7) 0 1 (0.3)
3 22 (7.6) 18 (6.2) 14 (4.3) 12 (3.7)
4 25 (8.6) 27 (9.3) 19 (5.9) 22 (6.8)
5 231 (80.2) 229 (79.5) 285 (89.0) 282 (88.1)
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premedication, which produced 95.5% 
diagnostically acceptable coronary seg-
ments compared to 89.8% with beta-
blocker premedication. In our study, 
image quality of the middle portion of 
the RCA and the LCX artery was lower 
than that of the other segments, due to 
their close proximity to the right and 
left atria, respectively. The LMCA and 
LAD arteries follow left ventricular mo-
tion, but their velocity of motion is sig-
nificantly lower than that of the RCA 
and the LCX artery, so high-quality 
images of the LMCA and LAD arteries 
could likely be obtained at higher heart 
rates (7, 17, 18). 
Our study had several limitations. 
First, the study population was rela-
tively small, and although the differ-
ences between groups were significant, 
further studies with larger series are re-
quired to confirm our results. Second, 
because of the contraindications, pa-
tient population selection was highly 
limited. Third, heart rate variability 
was not evaluated in our study. We 
also did not include coronary artery 
stenosis detection, which may have 
been biased due to an incomplete data 
set. In addition, a relative disadvan-
tage of oral ivabradine premedication 
is a delay time of approximately three 
days; however, this only becomes an 
issue in urgent cases. 
In conclusion, our study indicates 
that CTCA with oral ivabradine pre-
medication is feasible, and a safe and 
effective way of reducing heart rate to 
generate images of diagnostically ac-
ceptable quality in almost all coronary 
segments. Thus, ivabradine can suc-
cessfully substitute for beta-blockers, 
particularly in patients with contrain-
dications to beta-blockers. 
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